MarketCap
Facebook
X
Telegram
Sorrento Therapeutics Operating Cycle | SRNE
Annual Operating Cycle Sorrento Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125 | 118 | 204 | 356 | 234 | 34.9 | 118 | 65 | 53.7 | 188 | 24.9 | 42.2 | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 356 | 24.9 | 130 |
Quarterly Operating Cycle Sorrento Therapeutics
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 143 | - | 36 K | 31.3 K | 108 | 123 | 10.8 K | -80.4 K | -3.46 K | 123 | -2.5 K | -301 | -2.46 K | 91.1 | 169 | 215 | 207 | 40.2 | 189 | 305 | 145 | 9.89 | 1.65 | 43.2 | 36.6 | 38.5 | 69 | 172 | 120 | 61.6 | 74.7 | 70.2 | 76.3 | 83.7 | 52.4 | 86.2 | 52.6 | - | 433 | 253 | 161 | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36 K | -80.4 K | -185 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Vaxart
VXRT
|
187 | - | -25.06 % | $ 46.3 M |  USA |
 |
XOMA Corporation
XOMA
|
23.6 | - | - | $ 485 M | USA |
 |
Sesen Bio
SESN
|
391 | - | 7.29 % | $ 127 M | USA |
 |
Windtree Therapeutics
WINT
|
164 | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
25.5 | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
392 | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
6.22 | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Brickell Biotech
BBI
|
26 | - | -5.38 % | $ 6.06 M | USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
107 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
18.6 | - | - | $ 5.78 B |  Niderland |
 |
AbbVie
ABBV
|
350 | $ 293.87 | 0.19 % | $ 520 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
86.7 | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
33.4 | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Axon Enterprise
AXON
|
98.8 | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
456 | - | - | $ 83.9 M |  Canada |
 |
Liquidia Corporation
LQDA
|
36.8 | $ 51.37 | 7.31 % | $ 4.42 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
153 | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
81.3 | - | -3.76 % | $ 3.47 M | USA |
 |
Celldex Therapeutics
CLDX
|
43.4 | $ 30.68 | -1.81 % | $ 2.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
233 | $ 4.0 | -6.76 % | $ 48.8 M | Israel |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
361 | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
Eli Lilly and Company
LLY
|
433 | $ 1 432.7 | 1.47 % | $ 1.29 T | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
554 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mesoblast Limited
MESO
|
0.01 | $ 14.0 | -3.06 % | $ 16.9 B |  Australia |
 |
CorMedix
CRMD
|
439 | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
19.1 K | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
457 | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
263 | - | - | $ 521 M | USA |